IFNA1 and acute myeloid leukemia: A recent phase I clinical trial in humans have leveraged this effect by combining IFNɣ treatment with DLI, with promising safety data as well as evidence of increased MHC class II expression and improvement in T cell chimerism in four patients with relapsed MDS/AML (176, 177).